Cover Image

Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: insights from the EMPA-REG OUTCOME trial

Abstract Aim To explore the cardiovascular (CV) and kidney effects of empagliflozin in patients with different clinical phenotypes of diabetic kidney disease (DKD) (i.e. with the presence or absence of overt albuminuria) participating in the EMPA-REG OUTCOME trial. Materials and methods EMPA-REG OUT...

Full description

Saved in:
Bibliographic Details
Main Authors: Wanner, Christoph (Author) , Inzucchi, Silvio E. (Author) , Zinman, Bernard (Author) , Koitka-Weber, Audrey (Author) , Mattheus, Michaela (Author) , George, Jyothis T. (Author) , Eynatten, Maximilian von (Author) , Hauske, Sibylle J. (Author)
Format: Article (Journal)
Language:English
Published: 17 November 2020
In: Diabetes, obesity and metabolism
Year: 2020, Volume: 22, Issue: 12, Pages: 2335-2347
ISSN:1463-1326
DOI:10.1111/dom.14158
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1111/dom.14158
Verlag, kostenfrei, Volltext: https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.14158
Get full text
Author Notes:Christoph Wanner, Silvio E. Inzucchi, Bernard Zinman, Audrey Koitka-Weber, Michaela Mattheus, Jyothis T. George, Maximilian von Eynatten, Sibylle J. Hauske, EMPA-REG OUTCOME Investigators Empa
Description
Summary:Abstract Aim To explore the cardiovascular (CV) and kidney effects of empagliflozin in patients with different clinical phenotypes of diabetic kidney disease (DKD) (i.e. with the presence or absence of overt albuminuria) participating in the EMPA-REG OUTCOME trial. Materials and methods EMPA-REG OUTCOME randomized participants (1:1:1) to empagliflozin 10 mg, 25?mg or placebo, added to standard of care. Post hoc, patients with different clinical phenotypes of DKD at baseline were categorized in three subgroups: (a) overt DKD (overt albuminuria [urinary albumin-to-creatinine ratio of >300?mg/g] with any estimated glomerular filtration rate [eGFR]; n = 769); (b) non-overt DKD (kidney impairment [eGFR .05), consistent with the overall trial population findings. Empagliflozin also significantly reduced the yearly loss of eGFR, assessed by chronic slopes, in all subgroups. The adverse event profile of empagliflozin was similar across all subgroups. Conclusions Empagliflozin may improve CV and kidney outcomes and slow the progression of kidney disease in type 2 diabetes patients with DKD, irrespective of its clinical form, both with or without the presence of overt albuminuria.
Item Description:Gesehen am 20.10.2025
Physical Description:Online Resource
ISSN:1463-1326
DOI:10.1111/dom.14158

Similar Items